Dr. Agarwal’s Eye Hospital–AHCL merger decoded: – M&A lenses and shareholder optics

Opening Hook

In a world where consolidation is as trendy as K-dramas on Netflix, Dr. Agarwal’s just prescribed a merger of its Eye Hospital arm into Dr. Agarwal’s Health Care Ltd (AHCL). Numbers here aren’t blurry: ₹1,711 crore revenue in FY25, up 28% YoY (CRISIL report, investor presentation). Why does it matter? Because healthcare investors are squinting for scale stories in eye care, and this deal promises one unified giant across India and Africa. Stick around—things get sharper two scrolls down.

At a Glance

• AHCL revenue ₹1,711 cr (FY25) – 28% growth, sharper than Lasik.
• AEHL revenue ₹402 cr (FY25) – Tamil Nadu focus, strong 24% growth.
• Merger swap – 23 AHCL shares for 2 AEHL shares, ~15% premium.
• Target completion – Q2 FY27, subject to SEBI/NCLT approvals.
• Network – 293 facilities across India & Africa, 3 lakh+ surgeries annually.

Management’s Key Commentary

“The merger aligns stakeholder interests under one unified platform.”
Translation: Two boards, one cap table, less paperwork.

“EPS accretive from the first year of implementation.”
Translation: Trust us, synergies aren’t just buzzwords.

“AHCL is India’s largest eye care services chain.”
Translation: Narayana and Apollo may have size, but we own your cornea.

“AEHL has grown facilities 2.4x since FY22.”
Translation: Tamil Nadu expansion = Dr. Agarwal’s never sleeps.

“Merger enables integrated capital allocation for stronger growth.”
Translation: One big cheque book, fewer intercompany WhatsApp groups.

“Target to close by Q2 FY27 subject to approvals.”
Translation: Until then, keep the champagne on ice.

Numbers Decoded